Original Publication Date: 1 February, 2017
Publication / Source: Future Oncology
Authors: Elie El Rassy, Tarek Assi & Joseph Kattan
The treatment armamentarium of cancer has evolved tremendously in the last decades with the concept of targeted drugs . Immune checkpoint inhibitors (ICI) is a targeted treatment that deactivates the tumor-induced inhibition of the immune system . Unfortunately, ICI are administered continuously until disease progression or occurrence of limiting toxicity in view of the absence of data that specifies the length of ICI administration. The toxicity profile of ICI depends on the type of inhibitor used.